A Question Of Intent: How To Avoid US FDA Pitfalls With Academic Oncology Trials

Academic oncology centers and commercial sponsors should work together to ensure that studies begun without ‘registrational intent’ can nevertheless work for US FDA’s needs if circumstances change, a multi-stakeholder white paper urges.